Zai Lab Ltd — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Zai Lab reported Q2 2026 total revenue of $106.3M (down 3.7% YoY from $110.0M), with net product revenue of $105.8M up 11% sequentially. Net loss was $50.8M ($0.46 per ADS). Cash and investments totaled $717.5M as of June 30, 2026 vs. $761.3M on March 31, 2026 (decline of $43.8M in Q2). Pipeline advanced: zocilurtatug pelitecan (zoci) received FDA Fast Track and EMA Orphan Drug designations; TIVDAK approved in China; KarXT launched in mainland China; ZL-1503 Phase 1/1b ongoing with data expected H2 2026. Three registrational studies expected to be underway by year-end with potential first U.S. regulatory submission in 2027.
Why this rating
Revenue flat-to-declining YoY despite sequential QoQ growth; pipeline progression meaningful but pre-commercial; cash burn $43.8M/Q sustainable at current runway; near-term guidance neutral; clinical catalysts expected H2 2026–H1 2027.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.